Evaluation clinical-biochemical features of Parkinson’s disease
Objective: To study the features of the cytokine status under different forms and variants of PD course. Background: Parkinson’s disease is clinically heterogeneous; the etiology…Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri
Objective: Bacopa monnieri is largely treasured as a revitalizing herb used by Ayurvedic medical practitioners for almost 3000 years. The herb has been mentioned in…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily on Parkinson disease (PD) disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration…On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios
Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…‘PDSAFE’ – A multi-dimensional fall rehabilitation intervention for people with Parkinson’s with specialist physiotherapy training: qualitative exploration of physio’s experiences
Objective: To describe the experiences and views of physiotherapists on the specialist training and delivery of the PDSAFE intervention as part the falls prevention trial.…Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration
Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson
Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…Dual device aided therapy for patients with advanced Parkinson’s Disease: A case series
Objective: To describe the benefits of adding levodopa–carbidopa intestinal gel infusion (LCIG) therapy to Parkinson’s disease (PD) patients on deep brain stimulation (DBS). Background: Device-aided…Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys
Objective: To evaluate the effect of repeated OPC treatments, COMT inhibition versus plasma opicapone level, dose response of COMT inhibition, and systematic and central bioavailability…Association analysis of the nutritional status and serum nutritional index in patients with Parkinson’s disease
Objective: This study was conducted to determine the associations between the nutritional status and serum nutritional index and motor symptoms among patients with Parkinson’s disease(PD).…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.